New combo therapy offers hope for hard-to-treat stomach cancer
NCT ID NCT06085755
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people with advanced HER2-low stomach cancer that has not responded to earlier treatments. It tests a combination of two targeted drugs, trastuzumab deruxtecan (T-DXd) and afatinib, to see if they work better together. The goal is to shrink tumors and improve survival, while carefully monitoring safety. About 61 adults will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
Contact